Benjamin Huremagic

Benjamin Huremagic

Auto-generated profile, based on publicly available information

Benjamin Huremagic

Laboratory of Cytogenetics and Genome Research, Centre for Human Genetics, KU Leuven, Leuven, Belgium

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 August 2025 in European Journal of Human Genetics
Verified
Journal Article
Open access
PDF file
BHBenjamin Huremagic
Benjamin Huremagic
NSNishkala Sattanathan
Nishkala Sattanathan
MGMathilde Geysens
Mathilde Geysens
JHJanet Harwood
Janet Harwood
Jente VerbesseltJente Verbesselt
Jente Verbesselt
JVJoris Vermeesch
Joris Vermeesch
Access to large patient cohort data and biobanked resources is a catalyst for progress in genomics and biomedical research, increasing statistical power, and unlocking deeper insights—especially in areas like rare diseases and mental health. Responsible research necessitates maintenance of data privacy, regulatory compliance, and research standardization. It can appear that these guiding principles oppose each other and present barriers to responsible Open science. To address these critical challenges, we developed MINDDS-Connect, a federated data collaboration platform that integrates a web-based interface with decentralized Docker instances via a REST API. This architecture allows registered users to securely query samples across the platform’s network, and offers a tool to facilitate the formation of virtual multi-centric meta-cohorts and research collaboration. MINDDS-Connect allows institutions to retain data control while enabling collaborative research and meta-cohort analysis through standardized metadata fields. Its implementation across five European centers enhanced the accessibility of 900 samples, demonstrating its effectiveness in enabling cohort construction and promoting collaborative research. The platform provides a secure, open-source solution consistent with EU Open Science policies, advancing large-scale mental health research.

22 April 2024 in medRxiv
Verified
Preprint
Open access
PDF file
MGMathilde Geysens
Mathilde Geysens
BHBenjamin Huremagic
Benjamin Huremagic
ESErika Souche
Erika Souche
JBJeroen Breckpot
Jeroen Breckpot
KDKoenraad Devriendt
Koenraad Devriendt
JVJoris Vermeesch
Joris Vermeesch
Background A subset of developmental disorders (DD) is characterized by disease-specific genome-wide methylation changes. These episignatures inform about underlying pathogenic mechanisms and can be used to assess the pathogenicity of genomic variants as well as confirm clinical diagnoses. Currently, episignature detection requires the use of indirect methylation profiling microarrays. We hypothesized that long-read whole genome sequencing would not only enable the detection of single nucleotide variants and structural variants but also episignatures. Methods Genome-wide nanopore sequencing was performed in forty controls and twenty patients with confirmed or suspected episignature-associated DD, representing thirteen distinct diseases. Following variant and methylome calling, hierarchical clustering and dimensional reduction were used to determine the compatibility with microarray-based episignatures. Subsequently, we developed a support vector machine for each DD. Results Nanopore sequencing based methylome patterns were concordant with microarray-based episignatures. Our classifier identified episignatures in 17/20 disease samples and none of the controls. The remaining three patient samples were classified as controls by both our classifier and a commercial microarray assay. In addition, we identified all underlying pathogenic single nucleotide and structural variants and showed haplotype-aware skewed X-inactivation evaluation directs clinical interpretation. Conclusion This proof-of-concept study demonstrates nanopore sequencing enables concurrent haplotyped genomic and epigenomic analyses.